Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Recruiting · NCT06057402 · Registry updated 2026-07-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 4 | 2026-07-01 | NCT06057402 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Pfizer | 431 |
33 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.